Loading
Every dated change on the records linked to Rectal cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
First- and second-line metastatic colorectal cancer with fluoropyrimidine-based chemotherapy, only when targeted treatment or immunotherapy is unsuitable
Primary endpoint (sustained cCR at 12 months) met; rates pending congress presentation.
A milestone in how this cancer is treated.
3-year disease-free survival 76% in both arms; 3-year survival without total mesorectal excision 41% (induction) vs 53% (consolidation).
Three-year disease-free survival 64.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Previously untreated EGFR-expressing RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI
Previously untreated RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI
Delaying surgery after 5 x 5 Gy is non-inferior for local recurrence and has fewer postoperative complications.
First-line metastatic colorectal cancer with 5-FU chemotherapy
EGFR-expressing metastatic colorectal cancer; later restricted to RAS wild-type
EGFR-expressing metastatic colorectal cancer (later restricted to RAS wild-type)
5-year local recurrence 6% (preoperative) vs 13% (postoperative); overall survival unchanged.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.